Article Figures & Data
Figures
- FIGURE 1.
Biodistribution of 175 MBq of 68Ga-OPS202 (15 μg) 1 h after injection in patient 11 with NET of ileum. Currently, patient is in complete remission. (A) Whole-body PET scan. (B) Transaxial PET/CT slice at level of dashed line in A. There is low background activity in salivary glands, liver, and intestine.
- FIGURE 2.
Biodistribution of 188 MBq of 68Ga-OPS202 (15 μg) at 0.5, 1, 2, and 4 h after injection in patient 2 with ileal NET. PET maximum-intensity projections with constant linear gray scale show multiple liver metastases and subdiaphragmatic peritoneal deposits. Tumor and renal uptake persists over time, whereas organs such as spleen, lungs, and liver, along with urinary excretion, are progressively washed out. Tumor contrast was highest at 1 h after injection, whereas 4-h images suffer from poor count statistics. Remarkably low accumulation of 68Ga-OPS202 is seen in sst2 receptor–positive organs such as pituitary, spleen, adrenals, and uncinate process of pancreas. p.i. = after injection.
Tables
Parameter Data Mean age (y) 54.8 (SD, 14.7) Sex (n) Male 7 (58.3%) Female 5 (41.7%) Mean time since gastroenteropancreatic NET diagnosis (y) 4.8 (SD, 8.51) Grade (n) Low 7 (58.3%) Intermediate 5 (41.7%) Gastroenteropancreatic NET hormonal status (n) Functioning 5 (41.7%) Nonfunctioning 7 (58.3%) sst analog (n) Yes (all long-acting somatostatin analogs) 6 (50%) No 6 (50%) - TABLE 2
Mean Background Activity in Organs at 1 Hour After Injection of 15 μg (Visit 1) and 50 μg (Visit 2) of 68Ga-OPS202
SUVmax Organ Visit 1 Visit 2 P Liver 3.2 (0.8) 2.9 (0.7) <0.05 Stomach 4.2 (2.3) 3.0 (1.2) <0.05 Jejunoileum 3.5 (1.3) 2.9 (0.7) <0.05 Pancreas 3.2 (2.0) 2.6 (1.4) 0.052 Parotids 3.7 (1.9) 3.4 (1.7) 0.06 Right adrenal 7.4 (3.7) 6.3 (2.3) 0.09 Left adrenal 8.3 (3.9) 7.1 (3.5) 0.08 Pituitary 5.8 (1.8) 5.7 (2.0) 0.23 Thyroid 2.3 (1.2) 2.3 (0.7) 0.93 Lung 1.7 (0.6) 1.6 (0.6) 0.29 Mediastinum 1.7 (0.5) 1.5 (0.3) 0.18 Spleen 11.7 (4.2) 10.1 (2.3) 0.14 Data in parentheses are SDs.
Organ Residence time (min) Whole body 80.22 (4.38) Urinary bladder wall 5.16 (1.80) Liver 4.32 (1.20) Kidneys 3.42 (0.84) Lung 2.64 (0.60) Blood 2.40 (1.08) Spleen 1.62 (1.02) Red bone marrow* 1.32 (0.60) Stomach 1.08 (0.18) Lower large intestine 1.08 (0.18) Upper large intestine 1.08 (0.18) Small intestine 1.08 (0.18) Heart 0.72 (0.24) Pancreas 0.12 (0.06) Vertebral bodies (L2–L4) 0.12 (0.06) Adrenal glands 0.06 (0.000) Gallbladder 0.06 (0.000) ↵* Blood-based residence time calculation.
Data in parentheses are SDs.
Organ Dose coefficient (mGy/MBq) Urinary bladder wall 1.01E−01 (4.28E−02) Kidneys 8.43E−02 (3.13E−02) Spleen 6.02E−02 (4.73E−02) Lower large intestine wall 3.54E−02 (1.03E−02) Adrenal glands 2.99E−02 (1.16E−02) Upper large intestine wall 2.60E−02 (6.98E−03) Stomach wall 2.30E−02 (7.53E−03) Liver 2.18E−02 (8.66E−03) Lung 2.12E−02 (7.01E−03) Small intestine 1.89E−02 (4.50E−03) Pancreas 1.55E−02 (5.09E−03) Heart wall 1.47E−02 (3.83E−03) Osteogenic cells 1.39E−02 (3.55E−03) Gallbladder wall 1.22E−02 (3.10E−03) Uterus 1.19E−02 (1.72E−03) Red marrow 1.13E−02 (3.08E−03) Ovaries 1.10E−02 (1.68E−03) Testes 8.52E−03 (1.70E−03) Muscle 8.50E−03 (1.68E−03) Thymus 8.41E−03 (1.73E−03) Thyroid 8.04E−03 (1.73E−03) Breasts 7.45E−03 (1.70E−03) Brain 7.32E−03 (1.72E−03) Skin 7.13E−03 (1.69E−03) Data in parentheses are SDs.
Patient no. AE Intensity* Relationship 1 Urinary tract infection Grade 2 Unlikely 3 Abdominal pain Grade 1 Not related Urinary tract infection Grade 1 Not related Abnormal liver function test Grade 1 Unlikely 5 Eosinophilia Grade 1 Possible Fatigue Grade 1 Unlikely 7 Fatigue Grade 2 Unlikely 8 Nasopharyngitis Grade 1 Not related 11 Rash Grade 1 Possible Diarrhea Grade 1 Possible Headache Grade 1 Unlikely * According to version 4.03 of the Common Terminology Criteria for Adverse Events.
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- 68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study
- A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors
- A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors
- Head-to-Head Comparison of 68Ga-DOTA-JR11 and 68Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study
- International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
- Somatostatin Receptor Imaging of Neuroendocrine Tumors: From Agonists to Antagonists
- Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study